media – Page 12 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Leading blood equipment company, selling off mainline business

On December 3, 2024, Haemonetics announced that the company had agreed to sell its whole blood assets (whole blood collection, processing, and filtration solution portfolio) to GVS S.p.A for $67.1 million. GVS, a manufacturer providing filtering solutions for healthcare and life sciences, has agreed to pay $44.6 million upfront. The transaction also includes up to $22.5 million in contingent income payments over the next four years. 01. Sell off whole blood business and focus on plasma field According to the terms of this agreement, GVS will acquire all proprietary whole blood collection, processing, and filtration solutions from Haemonetics. At the same time, GVS will also take over Haemonetics’ manufacturing plant in Covina, California, which produces some of the aforementioned products. In addition, GVS also acquired the relevant equipment and assets of Haemonetics’ Boston headquarters located in Tijuana, Mexico. Previously, Haemonetics had announced plans to terminate its online blood collection business ...
- Source: drugdu
- 52
- December 10, 2024
Hengrui Medicine’s IL-17A monoclonal antibody price cut by 57%

Only three months after its launch, Hengrui Medicine’s IL-17A monoclonal antibody Funaqizumab has reduced its price. On December 2, the Jiangsu Provincial Public Resources Trading Center issued an announcement that the online prices of some drugs were adjusted, among which the price of Funaqizumab was reduced from 1,986 yuan per vial to 860 yuan, a reduction of more than 56%. As Funaqizumab has only been on the market for three months, Hengrui Medicine has chosen to reduce its price, which is rare. Of course, it is understandable that Funaqizumab was approved in August and failed to catch up with this year’s medical insurance negotiations, and faced considerable pressure. In China, Sicuzumab is one of the most innovative drugs that actively embraces medical insurance negotiations. Its successive price cuts have broken the limitations of the autoimmune drug market. In May this year, Novartis said that Secukinumab has covered more than 500,000 ...
- Source: drugdu
- 59
- December 10, 2024
Everest’s “hidden gold mine” emerges

The high value of EVER001 is related to the market it is in. The potential treatment population is huge, the clinical burden is heavy, and effective treatment is scarce, which determines that the field of kidney disease is a super blue ocean market. Take the primary membranous nephropathy market as an example. As the most common pathological type of adult kidney disease, there are nearly 2 million cases of primary membranous nephropathy in China, and the total number of patients in the United States, Europe, Japan and other countries exceeds 200,000. Primary membranous nephropathy can cause renal failure. The “Future landscape for the management of membranous nephropathy” published in the Journal of Clinical Nephrology in August 2023 showed that if left untreated, 14% of patients with persistent nephrotic syndrome may develop renal failure at 5 years, 35% at 10 years, and 41% at 15 years. Unfortunately, no specific drug has ...
- Source: drugdu
- 60
- December 10, 2024
To solve the problem of paying for sky-high-priced drugs, the US health insurance has set an example

“Sky-high” has almost become an exclusive adjective for gene therapy, and there is no most expensive, only more expensive. On August 17, 2022, the US FDA announced the approval of Zynteglo, a gene therapy developed by Bluebird, for the treatment of patients with β-thalassemia. Zynteglo is priced at $2.8 million, making it the most expensive therapy in the world at the time. On September 16 of that year, Skysona, another gene therapy of Bluebird, was approved by the FDA for the treatment of the rare neurological disease “brain adrenoleukodystrophy”, priced at $3 million. Subsequently, the FDA approved the listing of Hemgenix, a gene therapy jointly developed by CSL and UniQure, for the treatment of hemophilia B. The price of one dose is $3.5 million, once again breaking the record of the world’s most expensive drug. Despite the potential to solve the problem once and for all, the high price has ...
- Source: drugdu
- 58
- December 10, 2024
Hidden in the 10 billion market! Qianyuan Pharmaceutical’s first generic “antihypertensive drug” is approved for marketing

According to the official website of NMPA, the arginine perindopril tablets developed by Qianyuan Pharmaceutical’s subsidiary Qianyuan Baoling were approved for marketing, becoming the first domestic generic version of this product. In 2013, China’s total health expenditure was 3,186.9 billion yuan, of which the direct economic burden of hypertension accounted for 6.6%. According to statistics, the prevalence of hypertension in people over 18 years old in China has reached 27.5%, and the total number of patients is close to 300 million, but the treatment rate and control rate are only 40% and 16.9% respectively. This situation urgently needs more effective treatment strategies. The “National Primary Hypertension Prevention and Control Management Manual 2020 Edition” issued by the National Center for Cardiovascular Diseases mentioned: “Once diagnosed, it is recommended that all hypertensive patients start drug treatment immediately while intervening in lifestyle.” Drug means are crucial in the prevention and treatment of hypertension. ...
- Source: drugdu
- 52
- December 10, 2024
Expopharm

Organiser：AVOXA Time：September 16 – 18, 2025 Address：Ostfach 10 10 06, D-40001 Dusseldorf; Stockum Church Street 61, D-40474, Dusseldorf, Germany Exhibition hall：Dusseldorf Exhibition Center Product range: Pharmaceuticals: Various medications, wholesale trade in pharmaceuticals, home care products, diagnostics, diagnostic instruments, dietary products, hygiene products, cosmetics, pharmaceutical accessories and displays, pharmacy DP, pharmacy supplies About Expopharm： The German Pharmaceutical and Pharmaceutical Exhibition (Expopharm) is an international pharmaceutical trade exhibition that has established itself as a leading trade show for the European pharmaceutical industry. It is held alternately between Düsseldorf and Munich. Established in 1949 as a medical exhibition, Expopharm covers all areas of the pharmaceutical world such as medications, toiletries, food supplements, naturopathy, as well as pharmaceutical equipment and technical literature.
- Source: drugdu
- 97
- December 10, 2024
BoRui Pharmaceuticals’ Dienogest Tablets Approved for Market Access

Shanghai Securities News – Recently, BoRui Pharmaceuticals received approval from the National Medical Products Administration (NMPA) for its Dienogest tablets, which are considered to have passed consistency evaluation, with the approval number being H20249468. The product is marketed under the brand name BoLü® and is indicated for patients with endometriosis. Endometriosis is a common disease among women of childbearing age, and commonly used treatment options include non-steroidal anti-inflammatory drugs, combined oral contraceptives, GnRH agonists, and high-efficiency progestins (such as the levonorgestrel intrauterine system (LNG-IUS) and dienogest). The novel progestin Dienogest has a dual mechanism of action, working centrally and peripherally. It alleviates dysmenorrhea associated with endometriosis while also reducing the size of ovarian endometriotic cysts. Furthermore, the effect on reducing cysts becomes more pronounced with prolonged use. Dienogest also has effects against endometrial hyperplasia, inflammatory responses, and angiogenesis. Due to its low daily dosage, minimal impact on liver and kidney ...
- Source: drugdu
- 66
- December 9, 2024
Merck’s PD-1 Inhibitor Pembrolizumab Receives Fourth Lung Cancer Indication Approval in China

On December 3, Merck announced that its PD-1 inhibitor Pembrolizumab (brand name: Keytruda®) has been approved by the National Medical Products Administration (NMPA) in China for use in combination with platinum-based chemotherapy for neoadjuvant treatment, followed by continued use of Pembrolizumab as monotherapy for adjuvant treatment in patients with resectable stage II, IIIA, and IIIB non-small cell lung cancer (NSCLC). Previously, Pembrolizumab had received three indications for advanced non-small cell lung cancer in China. https://finance.eastmoney.com/a/202412043259018786.html
- Source: drugdu
- 62
- December 9, 2024
Fosun Pharma’s Surufatinib Injection New Indication Approved

On December 3, Fosun Pharma announced that its subsidiary, Hansoh Pharmaceutical, has received approval from the National Medical Products Administration for the marketing authorization application of Hansou® (Surufatinib Injection) in combination with Pemetrexed and Carboplatin for the first-line treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that is negative for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusion. https://finance.eastmoney.com/a/202412033257905182.html
- Source: drugdu
- 65
- December 9, 2024
Rgenta Therapeutics announced a strategic collaboration with GSK to jointly develop small molecule splicing regulators targeting RNA

Rgenta will receive cash advances and pre-exercise milestone payments, and is expected to receive milestone payments, royalties and potential equity investments Rgenta Therapeutics is a clinical-stage biotechnology company dedicated to developing a series of oral small molecule drugs targeting RNA targets for the treatment of cancer and neurological diseases. The company announced today that it has signed a multi-year multi-target strategic research collaboration agreement with GlaxoSmithKline (GSK) to advance the discovery and development of new small molecule splicing regulators targeting RNA in multiple disease areas such as tumors. Dr. Christopher Austin, Senior Vice President of Research Technology at GSK, said: “We are very excited about Rgenta’s differentiated approach to discovering and developing oral small molecule splicing regulators for high-value targets. We are committed to working with industry-leading companies to further enrich our existing expertise in the field of targeted RNA drugs. At the same time, we also look forward to ...
- Source: drugdu
- 53
- December 9, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.